Elapegademase
Appearance
Clinical data | |
---|---|
Trade names | Revcovi |
Other names | elapegademase-lvlr |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG |
Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.
It is a recombinant enzyme[1] that is administered weekly by intramuscular injection.[2]
Elapegademase may interact with PEGylated drugs.[2]
Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.[3][4][5] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[6]
References
- ^ "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
- ^ a b "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
- ^ "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Retrieved 26 December 2019.
- ^ "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
- ^ "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
- ^ "Elapegademase - Leadiant Biosciences". AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.
External links
- "Elapegademase". Drug Information Portal. U.S. National Library of Medicine.